ORIC PHARMACEUTICALS INC (ORIC)

Company Profile

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2020-04-24. The firm is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its clinical-stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency towards exon 20 insertion mutations, and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2).

Company Info

ORIC PHARMACEUTICALS INC

240 E. Grand Ave, 2nd Floor

South San Francisco CALIFORNIA 94080

P: 16503885600

CEO: Jacob M. Chacko

Employees: 93

Website: http://oricpharma.com/